Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julio MacHado

Geriatric Psychiatry Miami, FL Medical Doctor

NPI 1275579047 CMS profile 148215

15536 Sw 36Th Ter, Miami, FL 33185

Open in the dashboard

General payments

$7,672

368 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julio MacHado of Miami, FL is reported in the CMS Open Payments database as having received $7,672 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,659 68
2024 General $1,675 67
2023 General $1,835 81
2022 General $1,420 82
2021 General $168 9
2020 General $238 12
2019 General $678 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julio MacHado
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Julio MacHado were reported at $1,659. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Julio MacHado Geriatric Psychiatry median Middle half National median
2019 $678 $151 $47–$484 $163
2020 $238 $112 $30–$410 $114
2021 $168 $122 $35–$550 $132
2022 $1,420 $133 $54–$557 $149
2023 $1,835 $138 $61–$485 $160
2024 $1,675 $127 $51–$572 $164
2025 $1,659 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,213 75 payments
  2. Janssen Pharmaceuticals, Inc $947 34 payments
  3. Teva Pharmaceuticals USA, Inc. $789 19 payments
  4. Alkermes, Inc. $715 37 payments
  5. Otsuka America Pharmaceutical, Inc. $672 40 payments
  6. Lundbeck LLC $480 21 payments
  7. E.R. Squibb & Sons, L.L.C. $461 22 payments
  8. Sunovion Pharmaceuticals Inc. $411 37 payments
  9. ITI, Inc. $395 13 payments
  10. Indivior Inc. $331 15 payments
  11. Other $1,257 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,641 367 payments
  2. Education $32 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR $973 61 payments
  2. INVEGA SUSTENNA $931 33 payments
  3. ARISTADA Cns $688 36 payments
  4. ARISTADA Cns $688 36 payments
  5. LYBALVI $660 34 payments
  6. ARISTADA Cns $520 27 payments
  7. ARISTADA Cns $520 27 payments
  8. Austedo XR $509 6 payments
  9. REXULTI Psychiatry $497 31 payments
  10. REXULTI Psychiatry $417 18 payments
  11. Other $5,101 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

3,513

Median for Geriatric Psychiatry: 897

Drug cost

$243,639

Median for Geriatric Psychiatry: $35,920

Branded share of claims

10.6%

Median for Geriatric Psychiatry: 14.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 30 $68,128
Austedo Xr Deutetrabenazine Brand 11 $47,484
Vraylar Cariprazine Hcl Brand 23 $24,800
Rexulti Brexpiprazole Brand 15 $21,573
Lurasidone Hcl Generic 86 $17,514
Aripiprazole Generic 80 $15,185
Quetiapine Fumarate Er Quetiapine Fumarate Brand 57 $5,420
Fluphenazine Hcl Generic 45 $4,576
Quetiapine Fumarate Generic 270 $3,885
Oxcarbazepine Generic 98 $3,506

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 158 Part D prescribers listed as Geriatric Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$4,551

Medicare's payments for the services billed

Medicare patients

33

Average age 86

Services billed

55

20 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Depression 75%
Alzheimer's or dementia 73%
Heart failure 70%
Diabetes 67%
Ischemic heart disease 61%
Atrial fibrillation 61%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $180
  • Otsuka America Pharmaceutical, Inc. $157
$337 15 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $295
$295 30 —
VRAYLAR
  • AbbVie, Inc. $232
$232 23 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $154
$154 11 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record